The global immunohistochemistry market size is expected to reach a value of USD 3.2 billion by 2027, expanding at a CAGR of 7.8%, according to a new report by Grand View Research, Inc. Rising prevalence of chronic diseases, increasing regulatory approvals, and launch of technologically advanced immunohistochemistry (IHC) systems are expected to propel market growth over the forecast period.
IHC
has become a crucial technique and is widely applied in the diagnosis of
several chronic diseases such as cancer, infectious diseases, and cardiovascular
diseases (CVDs). Thus, a rise in the incidence of these chronic diseases has
led to an increase in the demand for IHC techniques. According to 2018 data
published by WHO, globally, cancer was one of the leading causes of mortality,
and in 2018 around 9.6 million deaths were registered due to cancer. The same
source also states that every year CVDs cause around 17.9 million deaths,
globally.
Furthermore,
increasing regulatory approval and launch of novel IHC products are expected to
support IHC market growth. For instance, in May 2019, F. Hoffmann-La Roche AG
launched its new VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody,
intended for the detection of ROS1-positive cancer cases. Additionally, in June
2019, the U.S. FDA approved the expanded use of Agilent Technologies’ PD-L1 IHC
22C3 pharmDx assay for the detection of head and neck squamous cell carcinoma
(HNSCC). This product is used in patients receiving treatment with Merck and
Co., Inc.’s Keytruda (Pembrolizumab).
However,
various limitations associated with immunohistochemistry techniques and the
high cost of automated IHC instruments are expected to hinder market growth
over the forecast period. Automated immunohistochemistry instruments for
disease diagnosis involve high setup costs. As a result, various emerging
economies still rely on cost-effective traditional diagnostics that are based
on immunostaining of thin tissue sections.
Full Research Report On Immunohistochemistry Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/immunohistochemistry-ihc-market
Immunohistochemistry
Market Report Highlights
- Antibodies
product segment held the largest market share in 2019 owing to increasing
product approval and their high adoption rate, leading to a high demand
for IHC techniques
- The
diagnostics application segment dominated the IHC market in 2019 and is
expected to witness the highest growth over the forecast period due to the
rising prevalence of chronic diseases
- Hospitals and
diagnostic laboratories dominated the market, by end use in 2019 owing to
an increase in the number of hospitals and diagnostic centers with
advanced infrastructure and the growing incidence of life-threatening
diseases
- North America
held the largest market share in 2019 due to the presence of
well-established healthcare infrastructure, favorable healthcare
reimbursement policies, and the presence of major players in U.S.
- Asia Pacific
is anticipated to exhibit fastest growth over the forecast period due to
the increasing prevalence of chronic diseases in countries such as China
and India
- Some of the
key players of immunohistochemistry market are Thermo Fisher Scientific,
Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation;
Perkinelmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology,
Inc.; Bio SB; Agilent Technologies, Inc.; and Abcam plc.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/immunohistochemistry-ihc-market/request/rs1
Immunohistochemistry
Market Segmentation
Grand View Research has
segmented the global immunohistochemistry market on the basis of product,
application, end use, and region:
Immunohistochemistry
(IHC) Product Outlook (Revenue, USD Million, 2016 - 2027)
- Antibodies
- Primary Antibodies
- Secondary Antibodies
- Equipment
- Slide Staining Systems
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Others
- Reagents
- Histological Stains
- Blocking Sera and Reagents
- Chromogenic Substrates
- Fixation Reagents
- Stabilizers
- Organic Solvents
- Proteolytic Enzymes
- Diluents
- Kits
Immunohistochemistry
(IHC) Application Outlook (Revenue, USD Million, 2016 - 2027)
- Diagnostics
- Cancer
- Infectious Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Diabetes Mellitus
- Nephrological Diseases
- Drug Testing
Immunohistochemistry
(IHC) End-use Outlook (Revenue, USD Million, 2016 - 2027)
- Hospitals and Diagnostic Laboratories
- Research Institutes
- Others
Immunohistochemistry
(IHC) Regional Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company, registered
in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment